After his sinister role on The Handmaid’s Tale, Josh Charles is switching gears to Fox’s upcoming small town show Best ...
On Monday, Chase Infiniti proved her breakout star status with a Golden Globe nomination for her role in One Battle After ...
Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...
A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...
The Handmaid's Tale cast is booked and busy with new projects — including the Testaments spinoff — after the Hulu series came ...
Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...
Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...
Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast ...